Evaluating Disease-Modifying Agents: A Simulation Framework for Alzheimer’s Disease
Authors:
- 15 August 2014
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 32 (11) , 1129-1139
Abstract
Considerable advances have been made in modeling Alzheimer’s disease (AD), with a move towards individual-level rather than cohort models and simulations that consider multiple dimensions when evaluating disease severity. However, the possibility that disease-modifying agents (DMAs) may emerge requires an update of existing modeling frameworks. The aim of this study was to develop a simulation allowing for economic evaluation of DMAs in AD. The model was developed based on a previously published, well-validated, discrete event simulation which measures disease severity on the basis of cognition, behaviour, and function, and captures the interrelated changes in these measures for individuals. The updated model adds one more domain, patient dependence, in addition to cognition, behaviour, and function to better characterize disease severity. Furthermore, the model was modified to have greater flexibility in assessing the impact of various important assumptions, such as the long-term effectiveness of DMAs and their impact on survival, on model outcomes. A validation analysis was performed to examine how well the model predicted change in disease severity among patients not receiving DMA treatment by comparing model results to those observed in two recent phase III clinical trials of bapineuzumab. In addition, various hypothetical scenarios were tested to demonstrate the improved features of the model. Validation results show that the model closely predicts the mean changes in disease severity over 18 months. Results from different hypothetical scenarios show that the model allows for credible assessment of those major uncertainties surrounding the long-term effectiveness of DMAs, including the potential impact of improved survival with DMA treatment. They also indicate that varying these assumptions could have a major impact on the value of DMAs. The updated economic model has good predictive power, but validation against longer-term outcomes is still needed. Our analyses also demonstrate the importance of designing a model with sufficient flexibility such that the model allows for assessment of the impact of key sources of uncertainty on the value of DMAs.Keywords
This publication has 28 references indexed in Scilit:
- Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data GapsInternational Journal of Alzheimer's Disease, 2012
- Enrichment and Stratification for Predementia Alzheimer Disease Clinical TrialsPLOS ONE, 2012
- Alzheimer’s disease: biological aspects, therapeutic perspectives and diagnostic toolsJournal of Physics: Condensed Matter, 2012
- New and emerging treatments for Alzheimer's diseaseExpert Opinion on Emerging Drugs, 2012
- Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulationBMC Neurology, 2012
- Estimation and Validation of a Multiattribute Model of Alzheimer Disease ProgressionMedical Decision Making, 2010
- The Effects of Patient Function and Dependence on Costs of Care in Alzheimer's DiseaseJournal of the American Geriatrics Society, 2008
- A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s diseaseNeurology, 2001
- A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patientsNeurology, 2001
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998